Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone

Abstract

Receptor activator of NF-κB ligand (RANKL) is a multifunctional cytokine known to affect immune and skeletal systems, as well as oncogenesis and metastasis1,2,3,4. RANKL is synthesized as a membrane-bound molecule, and cleaved into its soluble form by proteases5,6,7. As the soluble form of RANKL does not contribute greatly to bone remodelling or ovariectomy-induced bone loss8, whether soluble RANKL has a role in pathological settings remains unclear. Here we show that soluble RANKL promotes the formation of tumour metastases in bone. Mice that selectively lack soluble RANKL (Tnfsf11ΔS/ΔS)5,6,7,9 have normal bone homoeostasis and develop a normal immune system but display markedly reduced numbers of bone metastases after intracardiac injection of RANK-expressing melanoma and breast cancer cells. Deletion of soluble RANKL does not affect osteoclast numbers in metastatic lesions or tumour metastasis to non-skeletal tissues. Therefore, soluble RANKL is dispensable for physiological regulation of bone and immune systems, but has a distinct and pivotal role in the promotion of bone metastases.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Tnfsf11ΔS/ΔS mice do not exhibit any discernible osteopetrotic phenotype.
Fig. 2: Soluble RANKL is dispensable for lymph node development and mTEC differentiation.
Fig. 3: Soluble RANKL promotes bone metastasis of B16F10 melanoma cells without affecting osteoclastogenesis.
Fig. 4: Contribution of soluble RANKL to bone metastasis of breast cancer cells.

Data availability

The data that support the plots within this paper and other findings of this study are available from the corresponding authors upon reasonable request.

References

  1. 1.

    Okamoto, K. et al. Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol. Rev. 97, 1295–1349 (2017).

  2. 2.

    Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323 (1999).

  3. 3.

    Walsh, M. C. & Choi, Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front. Immunol. 5, 1–11 (2014).

  4. 4.

    Sigl, V., Jones, L. P. & Penninger, J. M. RANKL/RANK: from bone loss to the prevention of breast cancer. Open Biol. 6, 160230 (2016).

  5. 5.

    Lum, L. et al. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 274, 13613–13618 (1999).

  6. 6.

    Nakashima, T. et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 275, 768–775 (2000).

  7. 7.

    Hikita, A. et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand. J. Biol. Chem. 281, 36846–36855 (2006).

  8. 8.

    Xiong, J. et al. Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss. Nat. Commun. 9, 2909 (2018).

  9. 9.

    Nagashima, K. et al. Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat. Immunol. 18, 675–682 (2017).

  10. 10.

    Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50 (2000).

  11. 11.

    Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231–1234 (2011).

  12. 12.

    Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235–1241 (2011).

  13. 13.

    Danks, L. et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann. Rheum. Dis. 75, 1187–1195 (2016).

  14. 14.

    Onal, M. et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem. 287, 29851–29860 (2012).

  15. 15.

    Guerrini, M. M. et al. Inhibition of the TNF family cytokine RANKL prevents autoimmune inflammation in the central nervous system. Immunity 43, 1174–1185 (2015).

  16. 16.

    Lacey, D. L. et al. Osteoprotegrin ligand is cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176 (1998).

  17. 17.

    Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597–3602 (1998).

  18. 18.

    Takahashi, N. et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600–2602 (1988).

  19. 19.

    Miyamoto, T. et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κB ligand. Blood 96, 4335–4343 (2000).

  20. 20.

    Udagawa, N. et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141, 3478–3484 (2000).

  21. 21.

    Findlay, D. M. & Atkins, G. J. Relationship between serum RANKL and RANKL in bone. Osteoporos. Int. 22, 2597–2602 (2011).

  22. 22.

    Tsukasaki, M. et al. Host defense against oral microbiota by bone-damaging T cells. Nat. Commun. 9, 1–11 (2018).

  23. 23.

    Onder, L. et al. Lymphatic endothelial cells control initiation of lymph node organogenesis. Immunity 47, 80–92.e4 (2017).

  24. 24.

    Hikosaka, Y. et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29, 438–450 (2008).

  25. 25.

    Roodman, G. D. & Dougall, W. C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat. Rev. 34, 92–101 (2008).

  26. 26.

    Croucher, P. I., McDonald, M. M. & Martin, T. J. Bone metastasis: the importance of the neighbourhood. Nat. Rev. Cancer 16, 373–386 (2016).

  27. 27.

    Esposito, M., Guise, T. & Kang, Y. The biology of bone metastasis. Cold Spring Harb. Perspect. Med. 8, a031252 (2018).

  28. 28.

    Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692–696 (2006).

  29. 29.

    Sanchez-Sweatman, O. H., Lee, J., Or, F. W. & Singh, G. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur. J. Cancer 33, 918–925 (1997).

  30. 30.

    Nakai, Y. et al. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res. 7, 1 (2019).

  31. 31.

    Nakamura, M. et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144, 5441–5449 (2003).

  32. 32.

    Seeman, E. & Delmas, P. D. Bone quality—the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250–2261 (2006).

  33. 33.

    Kramer, I. et al. Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol. Cell. Biol. 30, 3071–3085 (2010).

  34. 34.

    Ominsky, M. S. et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J. Bone Miner. Res. 23, 672–682 (2008).

  35. 35.

    Zhang, L. et al. C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol. Lett. 3, 395–400 (2012).

  36. 36.

    Rachner, T. D. et al. Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in nonmetastatic breast cancer. Clin. Cancer Res. 25, 1369–1378 (2019).

Download references

Acknowledgements

We thank K. Miyazono, N. Komatsu, K. Kusubata, Y. Ogiwara, S. Nitta, K. Nagashima, M. Tsukasaki, M. Inoue, Y. Nakayama (The University of Tokyo), S. Sawa (Kyushu University), T. Nakashima (Tokyo Medical and Dental University) and M. Hattori (Tokyo Women’s Medical University) for thoughtful discussion and valuable technical assistance. This work was supported in part by a Practical Research Project for Rare/Intractable Diseases grant (JP17ek0109106) from the Japan Agency for Medical Research and Development; a Grant-in-Aid for Specially Promoted Research (15H05703), Young Scientists A (15H05653), Scientific Research B (16H05202 and 18H02919), Challenging Research (Pioneering) (17K19582) and the Japan Society for the Promotion of Science (JSPS) fellow (17J04280); Grants-in Aid for Research from the National Center for Global Health and Medicine (26-105 and 29-1001); The Japanese Society for Bone and Mineral Research Rising Stars Grant; and grants from Taiju Life Social Welfare Foundation, Astellas Research Support and Kobayashi Foundation for Cancer Research. T.A. was supported by a JSPS Research Fellowship for Young scientists.

Author information

T.A. performed most of the experiments, interpreted the results and prepared the manuscript. K.O. designed the study, interpreted the results and contributed to the manuscript preparation. M.T. and T.N. contributed to analyses of the thymus. A.S. assisted with bone analyses. R.M. generated genetically modified cell lines. Y.N., K.H. and S.E. contributed to analysis of the bone metastasis. T.O. generated genetically modified mice. H.T. directed the project and wrote the manuscript.

Correspondence to Kazuo Okamoto or Hiroshi Takayanagi.

Ethics declarations

Competing interests

The Department of Osteoimmunology is an endowment department, supported with an unrestricted grant from AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical, MIKI HOUSE and Noevir.

Additional information

Peer review information: Primary Handling Editor: Pooja Jha.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Supplementary Figs. 1–7

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark